Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|June 24, 2021
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical ReviewTheo Gülen, Cem Akin, Patrizia Bonadonna, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Haematologica|August 6, 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studiesRuben A Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Blood|August 8, 2024
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosisAyalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
The Lancet. Haematology|January 28, 2021
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling studyJavier I Muñoz-González, Iván Álvarez-Twose, María Jara-Acevedo, et al.
Cell Stem Cell|January 22, 2013
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibitionDaniel J Goff, Angela Court Recart, Anil Sadarangani, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2020
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the SkinDavid Fuchs, Alex Kilbertus, Karin Kofler, et al.
Blood Advances|January 28, 2026
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER studyJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
The Journal of Allergy and Clinical Immunology. in Practice|June 24, 2021
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical ReviewTheo Gülen, Cem Akin, Patrizia Bonadonna, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Haematologica|August 6, 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studiesRuben A Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Blood|August 8, 2024
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosisAyalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
The Lancet. Haematology|January 28, 2021
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling studyJavier I Muñoz-González, Iván Álvarez-Twose, María Jara-Acevedo, et al.
Cell Stem Cell|January 22, 2013
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibitionDaniel J Goff, Angela Court Recart, Anil Sadarangani, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2020
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the SkinDavid Fuchs, Alex Kilbertus, Karin Kofler, et al.
Blood Advances|January 28, 2026
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER studyJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Pageof 21